Teva Pharmaceutical Industries Limited
TEVA
677 hedge funds and large institutions have $24.7B invested in Teva Pharmaceutical Industries Limited in 2026 Q2 according to their latest regulatory filings, with 84 funds opening new positions, 276 increasing their positions, 197 reducing their positions, and 54 closing their positions.
179% more capital inflows, than outflows
Capital inflows: $3.4B | Capital outflows: $1.22B
92% more call options, than puts
Call options by funds: $724M | Put options by funds: $378M
56% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 54
40% more repeat investments, than reductions
Existing positions increased: 276 | Existing positions reduced: 197
5.18% more ownership
Funds ownership: 57.84% → 63.01% (+5.2%)
4% more funds holding
Funds holding: 654 → 677 (+23)
4% less funds holding in top 10
Funds holding in top 10: 26 → 25 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Meitav Investment House
Bene-Beraq,
Israel
|
+$331M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
+$172M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$126M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$123M |
| 5 |
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet
Tel Aviv,
Israel
|
+$97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lingotto Investment Management
London,
United Kingdom
|
-$252M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$95.7M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
-$69.8M |
| 4 |
NM
NWI Management
New York
|
-$67.4M |
| 5 |
PointState Capital
New York
|
-$59.5M |
TEVA Hedge Fund Activity: Q2 2026 in Review
677 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceutical Industries Limited (TEVA) for Q2 2026, worth a combined $24.7B — up 23% from $20.1B a quarter earlier.
Buyers outnumbered sellers: 84 funds opened new TEVA positions and 54 closed out — a net gain of 30 holders — while 276 added to existing stakes and 197 trimmed.
The largest buyer was Meitav Investment House, opening a new position worth an estimated $331M. The largest seller was Lingotto Investment Management, cutting an estimated $252M.
- 677 institutional investors held Teva Pharmaceutical Industries Limited (TEVA) as of Q2 2026, up from 654 in Q1 2026.
- Funds reported $24.7B of Teva Pharmaceutical Industries Limited stock for Q2 2026, up 23% quarter-over-quarter.
- 84 funds opened new Teva Pharmaceutical Industries Limited positions in Q2 2026 and 54 closed out, a net change of +30 holders.
- The largest Teva Pharmaceutical Industries Limited buyer in Q2 2026 was Meitav Investment House, an estimated $331M added.
- The largest Teva Pharmaceutical Industries Limited seller in Q2 2026 was Lingotto Investment Management, an estimated $252M sold.
Based on aggregated 13F filings for Q2 2026.